Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$1.31
-4.7%
$2.61
$1.27
$8.08
$97.61M3.111.40 million shs1.13 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$0.75
+10.7%
$1.12
$0.66
$7.14
$86.28M2.262.31 million shs3.61 million shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$14.32
-0.3%
$17.58
$5.22
$27.38
$179.73M0.74120,435 shs183,916 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$4.41
-9.6%
$4.30
$1.69
$6.07
$678.88M1.371.80 million shs3.87 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-4.73%-25.14%-46.09%-66.58%-83.42%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
+10.72%-11.35%-16.82%-58.17%-89.26%
LifeVantage Co. stock logo
LFVN
LifeVantage
-0.28%-0.69%-11.44%-19.51%+133.22%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-9.63%-20.97%+16.98%+22.16%+112.02%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
1.6477 of 5 stars
3.32.00.00.00.62.50.6
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
3.398 of 5 stars
3.11.00.04.71.22.50.6
LifeVantage Co. stock logo
LFVN
LifeVantage
3.0338 of 5 stars
3.51.01.72.70.02.50.0
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.2355 of 5 stars
4.41.00.04.23.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.60
Moderate Buy$12.50854.20% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.22
Hold$5.43621.02% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50112.99% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.80
Moderate Buy$6.1038.32% Upside

Current Analyst Ratings Breakdown

Latest LFVN, FATE, CCCC, and XERS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/7/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.00
3/7/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.00 ➝ $6.50
3/7/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $4.00
3/7/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.60 ➝ $8.00
3/6/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$5.00 ➝ $3.00
3/6/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.00
3/6/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00
3/6/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/14/2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
1/29/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $6.00
1/14/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.58M2.61N/AN/A$4.07 per share0.32
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$13.63M6.33N/AN/A$3.74 per share0.20
LifeVantage Co. stock logo
LFVN
LifeVantage
$212.15M0.85$0.75 per share19.03$2.38 per share6.02
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M3.34N/AN/A($0.05) per share-88.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$132.49M-$1.51N/AN/AN/A-313.35%-42.45%-27.55%5/6/2025 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$160.93M-$1.64N/AN/AN/A-1,325.43%-45.88%-33.95%5/8/2025 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.5625.57N/A3.46%34.29%15.04%4/30/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$62.26M-$0.38N/AN/AN/A-33.69%N/A-17.38%5/8/2025 (Estimated)

Latest LFVN, FATE, CCCC, and XERS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2025N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.1633N/AN/AN/A$60.99 millionN/A
3/5/2025Q4 2024
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 million
2/27/2025Q4 2024
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.44-$0.49-$0.05-$0.49$4.43 million$5.18 million
2/5/2025Q2 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.14$0.22+$0.08$0.19$67.41 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.161.12%N/A28.57%N/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A

Latest LFVN, FATE, CCCC, and XERS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/3/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.040.7%3/3/20253/3/20253/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
6.31
6.31
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.29
8.29
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.79
1.29

Institutional Ownership

CompanyInstitutional Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.55%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5.00%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15070.99 million64.55 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550114.60 million108.20 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.55 million9.96 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290153.94 million142.28 millionOptionable

Recent News About These Companies

Xeris Announces Changes to Its Board of Directors
12 Best Stocks to Invest in for a Stock Market Game

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$1.31 -0.07 (-4.73%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$1.30 -0.01 (-0.76%)
As of 04/4/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$0.75 +0.07 (+10.72%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$0.75 0.00 (-0.39%)
As of 04/4/2025 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$14.32 -0.04 (-0.28%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$14.32 0.00 (0.00%)
As of 04/4/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$4.41 -0.47 (-9.63%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$4.34 -0.07 (-1.47%)
As of 04/4/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.